How can we provide the best care for our patients with immune thrombocytopenic pupura?

George, James N.; Veseley, Sara K.; Vesely, Sara K
April 2004
Mayo Clinic Proceedings;Apr2004, Vol. 79 Issue 4, p456
Academic Journal
Discusses how physicians can know the best available evidence for treating patients with immune thrombocytopenic purpura (ITP). Comprehensive review on the management of ITP in adults by Stasi and Provan; Objective method of determining expert opinion; Quantitative assessment of responses to clinical scenarios by a panel of experts.


Related Articles

  • Treatment options for chronic immune thrombocytopenic purpura. Pruemer, Jane // American Journal of Health-System Pharmacy;1/16/2009, Vol. 66 Issue S2, pS3 

    The article offers information on treatment options for chronic immune thrombocytopenic purpura (ITP). It states that ITP is an autoimmune disorder characterized by thrombocytopenia due to increased platelet destruction and decreased platelet production. It also mentions that severe...

  • European Society of Hematology.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p5 

    The article reports on the results of a study which compared Nplat or romiplostim to the medical standard of care in nonsplenoctomized adult patients with chronic immune thrombocytopenic purpura (ITP), released by Amgen Inc. Results revealed that Nplat substantially decreased the incidences of...

  • Treatment Options for Chronic Immune Thrombocytopenic Purpura.  // American Journal of Health-System Pharmacy;1/16/2009, Vol. 66 Issue S2, pS22 

    A quiz concerning the treatment options for chronic immune thrombocytopenic purpura is presented.

  • Eltrombopag Tablets (Promacta). Elliot, William T.; Chan, James // Internal Medicine Alert;3/15/2009, Vol. 31 Issue 5, p37 

    The article presents a drug study of Eltrombopag Tablets (Promacta), a thrombopoietin (TPO) receptor agonist. The drug is intended for thrombocytopenia in patients associated with chronic immune (idiopathic) thrombocytopenia purpura. Moreover, it also provides the drug's dosage, potential...

  • Diagnosis and management of chronic ITP: comments from an ICIS expert group. Grainger, John David; Bolton-Maggs, Paula H. B.; Godeau, Bertrand; Bussel, Jim; Donato, Hugo; Elalfy, Mohsen; Hainmann, Ina; Matzdorff, Axel; Müller-Beissenhirtz, Hannes; Rovó, Alicia; Tichelli, Andre; Müller-Beissenhirtz, Hannes; Rovó, Alicia // Annals of Hematology;Jul2010, Vol. 89, p11 

    Immune thrombocytopenia (ITP) is a common disorder in children and adults. In a patient with newly diagnosed ITP, the treatment strategy is relatively well defined. Second-line treatments are more controversial, and the management of chronic ITP is even more so. During the 3rd ICIS Expert...

  • PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Griesshammer, M.; Klippel, S.; Strunck, E.; Temerinac, S.; Mohr, U.; Heimpel, H.; Pahl, H. L. // Annals of Hematology;Jun2004, Vol. 83 Issue 6, p364 

    Essential thrombocythemia (ET) is a heterogeneous disorder. For example, the growth of erythropoietin-independent erythroid colonies, termed “endogenous erythroid colonies (EECs)”, has previously been observed in only 50% of ET patients. We have recently described the overexpression...

  • Is romiplostim an alternative treatment for Immune Thrombocytopenic Purpura (ITP)? Stoicescu, Claudiu // Maedica - a Journal of Clinical Medicine;2009, Vol. 4 Issue 2, p172 

    The article provides information on the effects of romiplostim in the treatment of Immune Thrombocytopenic Purpura (ITP). It states that ITP is a chronic autoimmune disorder which triggers platelet destruction, causes mucocutaneous bleeding, and low platelet count. It concludes that romiplostim...

  • Platelet Transfusions in Infants with Necrotizing Enterocolitis Do Not Lower Mortality but May Increase Morbidity. Kenton, Alexander B; Hegemier, Suzanne; Smith, E O'Brian; O'Donovan, Donough J; Brandt, Mary L; Cass, Darrell L; Helmrath, Michael A; Washburn, Kimberly; Weihe, Elizabeth K; Fernandes, Caraciolo J // Journal of Perinatology;Mar2005, Vol. 25 Issue 3, p173 

    OBJECTIVE:: Necrotizing enterocolitis (NEC), a serious multisystemic inflammatory disease most commonly seen in premature neonates, is often associated with thrombocytopenia. Infants with severe forms of NEC commonly have platelet counts of less than 50,000/mm3, occasionally less than...

  • Economic Assessment of Thrombocytopenia: CATCH Registry. Eisenstein, Eric L.; Honeycutt, Emily F.; Anstrom, Kevin J.; Becker, Richard C.; Granger, Christopher B.; Rao, Sunil V.; Jolicoeur, Marc E.; Ohman, E. Magnus // Journal of Medical Systems;Jun2010, Vol. 34 Issue 3, p379 

    Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics